Safety of nab-paclitaxel plus sunitinib: Analysis of three cases

Arkadiusz Z Dudek, Sheila P Nguyen

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Background: Second-line treatment options are limited in controlling advanced thoracic cancer in patients who have progressed following first-line chemotherapy. Case Report: The safety of combination therapy with nab-paclitaxel, an albumin-bound paclitaxel, and sunitinib, a tyrosine kinase receptor inhibitor, was evaluated retrospectively in three patients with advanced, previously treated metastatic esophageal cancer, non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), respectively. Results: Grade 3 and 4 toxicities were mainly hematological and manageable. A notable improvement in cancer symptoms and reduction in tumor size were seen in all three patients. Conclusion: Based on the easily managed toxicities and apparent efficacy of the regimen of weekly nab-paclitaxel and daily sunitinib, we conclude that further evaluation is warranted to assess the efficacy of this combination therapy in previously chemotherapy-treated patients with advanced thoracic cancer.

Original languageEnglish (US)
Pages (from-to)3099-3105
Number of pages7
JournalAnticancer Research
Volume28
Issue number5 B
StatePublished - Sep 1 2008

Keywords

  • Chemotherapy
  • Esophageal cancer
  • Lung cancer
  • Taxane
  • Tyrosine kinase inhibitor

Fingerprint Dive into the research topics of 'Safety of nab-paclitaxel plus sunitinib: Analysis of three cases'. Together they form a unique fingerprint.

Cite this